A new study found that continuous infusion of inotropic medication can be safely administered at home or in hospice to patients with terminal heart failure as part of a plan to provide them with a better quality of life during end stages.

The study found that 64.5% of terminal heart failure patients receiving care through an inotropic infusion program were able to spend their final days at home or in hospice rather than in a hospital or other medical facility. That rate compared with 35.9% in an age- and sex-adjusted national sample.

The study authors noted that guidelines from the American College of Cardiology and American Heart Association allow for infusion of inotropic medication for patients with terminal heart failure to keep them comfortable. As part of the program in the study, nurses, pharmacists and other healthcare professionals worked closely with patients' physicians to manage symptoms and provide comprehensive care through home nursing visits and infusion pharmacist and nursing support.

According to the study authors, the findings have broader implications beyond the higher quality of life patients may experience through these home-care services. Continuous inotropic infusion therapy can reduce ED visits, prevent exacerbation of symptoms that require readmission to the hospital and reduce medical costs.

The study appeared in the American Journal of Hospice & Palliative Medicine. To read a summary and access the study via subscription or purchase, visit http://bit.ly/zc137P.